NASDAQ: SLNO - Soleno Therapeutics, Inc.

Rentabilität für sechs Monate: +28.9%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Soleno Therapeutics, Inc.


Über das Unternehmen Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.


IPO date 2014-11-13
ISIN US8342033094
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://soleno.life
Цена ао 48.97
Preisänderung pro Tag: +0.3571% (70)
Preisänderung pro Woche: +18.99% (59.04)
Preisänderung pro Monat: +42.38% (49.34)
Preisänderung über 3 Monate: +65.14% (42.54)
Preisänderung über sechs Monate: +28.9% (54.5)
Preisänderung pro Jahr: +82.37% (38.52)
Preisänderung über 3 Jahre: +34 168.29% (0.205)
Preisänderung über 5 Jahre: +4 183.54% (1.64)
Preisänderung seit Jahresbeginn: +55.08% (45.3)

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 7.43 1
P/E 0 0
EV/EBITDA -12.41 0
Gesamt: 1.38

Effizienz

Name Bedeutung Grad
ROA, % -68.74 0
ROE, % -87.35 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0817 10
Gesamt: 9.2

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -51866.73 0
Rentabilität Ebitda, % 132.89 10
Rentabilität EPS, % 18.94 3
Gesamt: 6.6

Institutionen Volumen Aktie, %
Vivo Capital, LLC 8418093 25.93
Nantahala Capital Management, LLC 5712702 17.6
Perceptive Advisors LLC 3074542 9.47
Carlyle Group Inc. 2857804 8.8
Janus Henderson Group PLC 2523897 7.78
Adage Capital Partners GP L.L.C. 1826814 5.63
Vestal Point Capital, LP 1300000 4
Vanguard Group Inc 969622 2.99
Balyasny Asset Management LLC 926876 2.86
Avoro Capital Advisors LLC 785000 2.42

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
iShares Morningstar Small-Cap Growth ETF 0.04077 572.1 0.72598
iShares Morningstar Small-Cap ETF 0.02055 391.25 1.60498
0.03481.681.17



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Anish Bhatnagar M.D. President, CEO, COO & Director 1.06M 1970 (55 Jahre)
Mr. James H. MacKaness Chief Financial Officer 640k 1964 (61 Jahr)
Dr. Neil M. Cowen M.B.A., Ph.D. Senior Vice President of Drug Development N/A
Ms. Kristen Yen M.S. Senior Vice President of Clinical Operations 317.19k 1969 (56 Jahre)
Ms. Meredith Manning M.B.A. Chief Commercial Officer N/A 1972 (53 Jahr)
Ms. Patricia C. Hirano M.P.H. Senior Vice President of Regulatory Affairs 493k 1966 (59 Jahre)
Ms. Lauren Budesheim Vice President of People N/A
Dr. Michael Huang M.D. Senior Vice President of Clinical Development N/A 1974 (51 Jahr)
Dr. Raymond W. Urbanski M.D., Ph.D. Chief Development Officer 1959 (66 Jahre)

Adresse: United States, Redwood City. CA, 203 Redwood Shores Parkway - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://soleno.life